These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 33341915

  • 1. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI.
    Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, Sareshgi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, Kramer G, Shariat SF, Beyer T, Hartenbach M, Hacker M.
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1795-1805. PubMed ID: 33341915
    [Abstract] [Full Text] [Related]

  • 2. The Challenge of External Generalisability: Insights from the Bicentric Validation of a [68Ga]Ga-PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference.
    Ghezzo S, Bharathi PG, Duan H, Mapelli P, Sorgo P, Davidzon GA, Bezzi C, Chung BI, Samanes Gajate AM, Thong AEC, Russo T, Brembilla G, Loening AM, Ghanouni P, Grattagliano A, Briganti A, De Cobelli F, Sonn G, Chiti A, Iagaru A, Moradi F, Picchio M.
    Cancers (Basel); 2024 Dec 07; 16(23):. PubMed ID: 39682289
    [Abstract] [Full Text] [Related]

  • 3. Utility of Multiparametric Prostate MRI to Predict Regional or Distant Metastatic Disease Against Conventional Staging Using CT and Bone Scintigraphy or 68Ga-PSMA PET in Intermediate-to-High-Risk Prostate Cancer.
    Nguyenhuy M, Chan XQ, Homewood D, Ogluszko C, Dundee P, Corcoran N.
    Cureus; 2024 Nov 07; 16(11):e73607. PubMed ID: 39677149
    [Abstract] [Full Text] [Related]

  • 4. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
    Spohn SKB, Farolfi A, Schandeler S, Vogel MME, Ruf J, Mix M, Kirste S, Ceci F, Fanti S, Lanzafame H, Serani F, Gratzke C, Sigle A, Combs SE, Bernhardt D, Gschwend JE, Buchner JA, Trapp C, Belka C, Bartenstein P, Unterrainer L, Unterrainer M, Eiber M, Nekolla SG, Schiller K, Grosu AL, Schmidt-Hegemann NS, Zamboglou C, Peeken JC.
    Eur J Nucl Med Mol Imaging; 2022 Dec 07; 50(1):218-227. PubMed ID: 35984452
    [Abstract] [Full Text] [Related]

  • 5. Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
    Şam Özdemir M, Kaya N, Savun M, Keskin ET, Yüzkan S, Arslan FZ, Budak B, Omak Ö, Yardımcı AH, Özdemir H.
    World J Surg Oncol; 2024 Dec 20; 22(1):339. PubMed ID: 39707383
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH.
    Clin Orthop Relat Res; 2024 Dec 01; 482(12):2193-2208. PubMed ID: 39051924
    [Abstract] [Full Text] [Related]

  • 7. Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.
    Hofman MS, Kasivisvanathan V, Link E, Buteau J, Roberts MJ, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Iravani A, Williams S, O'Brien J, Lawrentschuk N, Murphy DG.
    Eur Urol Oncol; 2024 Nov 28. PubMed ID: 39613566
    [Abstract] [Full Text] [Related]

  • 8. Integrating PET/CT, radiomics and clinical data: An advanced multi-modal approach for lymph node metastasis prediction in prostate cancer.
    Öğülmüş FE, Almalıoğlu Y, Tamam MÖ, Yıldırım B, Uysal E, Numanoğlu Ç, Özçevik H, Tekin AF, Turan M.
    Comput Biol Med; 2025 Jan 28; 184():109339. PubMed ID: 39522134
    [Abstract] [Full Text] [Related]

  • 9. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study.
    Pabst KM, Mei R, Lückerath K, Hadaschik BA, Kesch C, Rawitzer J, Kessler L, Bodensieck LS, Hamacher R, Pomykala KL, Fanti S, Herrmann K, Fendler WP.
    Eur J Nucl Med Mol Imaging; 2024 Dec 28; 52(1):342-353. PubMed ID: 39207485
    [Abstract] [Full Text] [Related]

  • 10. Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer.
    Zamboglou C, Bettermann AS, Gratzke C, Mix M, Ruf J, Kiefer S, Jilg CA, Benndorf M, Spohn S, Fassbender TF, Bronsert P, Chen M, Guo H, Wang F, Qiu X, Grosu AL.
    Eur J Nucl Med Mol Imaging; 2021 Jun 28; 48(6):1987-1997. PubMed ID: 33210239
    [Abstract] [Full Text] [Related]

  • 11. Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management.
    Abrahamsen BS, Tandstad T, Aksnessæther BY, Bogsrud TV, Castillejo M, Hernes E, Johansen H, Keil TMI, Knudtsen IS, Langørgen S, Selnæs KM, Bathen TF, Elschot M.
    J Magn Reson Imaging; 2025 Jan 28; 61(1):466-477. PubMed ID: 38679841
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A novel tool to predict lymph node metastasis in patients with prostate cancer based on clinical and 68Ga-PSMA PET/CT parameters.
    Dekalo S, Kuten J, Bashi T, Savin Z, Mano R, Beri A, Nevo A, Wasserman O, Mabjeesh NJ, Ziv-Baran T, Even-Sapir E, Yossepowitch O.
    Can Urol Assoc J; 2024 Dec 09. PubMed ID: 39661182
    [Abstract] [Full Text] [Related]

  • 14. Does the SORG Machine-learning Algorithm for Extremity Metastases Generalize to a Contemporary Cohort of Patients? Temporal Validation From 2016 to 2020.
    de Groot TM, Ramsey D, Groot OQ, Fourman M, Karhade AV, Twining PK, Berner EA, Fenn BP, Collins AK, Raskin K, Lozano S, Newman E, Ferrone M, Doornberg JN, Schwab JH.
    Clin Orthop Relat Res; 2023 Dec 01; 481(12):2419-2430. PubMed ID: 37229565
    [Abstract] [Full Text] [Related]

  • 15. An arterial spin labeling-based radiomics signature and machine learning for the prediction and detection of various stages of kidney damage due to diabetes.
    Ma F, Shao X, Zhang Y, Li J, Li Q, Sun H, Wang T, Liu H, Zhao F, Chen L, Chen J, Zhou S, Ji Q, Yu P.
    Front Endocrinol (Lausanne); 2024 Dec 01; 15():1333881. PubMed ID: 39624821
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer.
    Dinckal M, Ergun KE, Kalemci MS, Guler E, Tokac R, Ordu S, Ogut N, Ozgul S, Sanli O, Sen S, Turna B.
    Prostate; 2025 Jan 01; 85(1):48-57. PubMed ID: 39345022
    [Abstract] [Full Text] [Related]

  • 19. A Comprehensive Analysis of Volumetric 68Ga-PSMA PET/CT Parameters, Clinical and Histopathologic Features: Evaluation of the Predictive Role.
    Mutevelizade G, Parlak Y, Sezgin Arıkbası C, Gümüşer G, Sayit E.
    Mol Imaging Radionucl Ther; 2024 Jun 28; 33(2):68-76. PubMed ID: 38949389
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.